Sector Alpha Week of 2026-07-31
Sector Alpha — machine-written from the numbers · Data as of 2026-07-31

UPL Ltd

UPL
Pesticides/Agrochemicals

UPL Ltd's earnings have outrun its stock. EPS grew +114.5% in a year against a −9.1% price move.

The sharpest disagreement: annual EPS moved +114.5% against a −9.1% price move — the market has not yet caught up with the delivery.

The price is in a downtrend (20 weeks in) while the P/E sits at the 75th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +19.9% year on year, and 346% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
partial read
Price
₹604
−9.1% 1Y
P/E
28.3×
75th pctile
of its own 10-year range
Revenue (Mar 26)
₹18,335 Cr
+17.7% YoY
Profit (Mar 26)
₹1,294 Cr
+19.9% YoY
Operating margin
19.0%
−1.0 pp YoY
ROCE
10%
FY26
ROIC
7.9%
vs WACC 12.0% → −4.1 pp
Cash conversion
346%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

UPL Ltd trades at ₹604, in a downtrend and 20 weeks into that stage. That is −6.9% against its own 200-day average. It sits at 16% of a 52-week range of ₹565 to ₹805. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (26 weeks and counting).

Today the stock is in a downtrend — week 20 of stage 4, confirmed. At ₹604 it trades −6.9% versus its 200-day average and sits at 16% of its 52-week range (₹565–₹805).

Jul 26: ₹604 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−6.9% versus the 200-day line, week 20 of stage 4
Price50-day avg200-day avg
S4S2S2S4₹834₹728₹621₹515₹408₹604₹649Jul 23May 24Feb 25Nov 25Jul 26
S4S2S2S4₹834₹728₹621₹515₹408₹604₹649Jul 23Feb 25Jul 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (546 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 16Jul 26

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +115% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (26 weeks and counting; last ahead the week of 2026-02-20) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

UPL Ltd trades at 28.3× P/E, at the pricey end of its own range (75th percentile). Its long-run median P/E is 21.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 28.3× is at the pricey end of its own range (75th percentile), against a long-run median of 21.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 28.3× vs a 21.1× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 10.4-year window; loss-period spikes above 45× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (75th percentile)
P/EMedianEPS (TTM) (quarterly)
48.0×₹55.138.6×₹41.329.2×₹27.519.9×₹13.810.5×₹0.0×28.30×₹21Mar 16Jun 18Oct 20Feb 23Jul 26
48.0×₹55.138.6×₹41.329.2×₹27.519.9×₹13.810.5×₹0.0×28.30×₹21Mar 16Oct 20Jul 26
P/E
28.3×
75th percentile of 10y
PEG
0.83
derived from 3-year earnings growth

Why the multiple sits where it does: over the past year annual EPS moved +114.5% against a −9.1% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −4.9%/yr price move, ~−10.3%/yr came from earnings growth and ~+5.4 pp from the multiple (expanding); over 10y, of the +4.2%/yr price move, ~+4.4%/yr came from earnings growth and ~−0.2 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

UPL Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 10.9% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.

Growth, year by year: revenue +11.2% in FY26, profit +170.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
70%196%46%105%22%14%−2.1%−77%−26%−168%%%11.2%170.7%FY16FY21FY26
70%196%46%105%22%14%−2.1%−77%−26%−168%%%11.2%170.7%FY16FY21FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising
RevenueProfitEPS
14%342%4.7%190%−4.2%38%−13%−114%−22%−266%%%11.2%170.7%114.6%Jun 23Sep 24Mar 26
14%342%4.7%190%−4.2%38%−13%−114%−22%−266%%%11.2%170.7%114.6%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
12%9.2%6.8%4.3%1.9%%10.9%Jun 23Dec 23Sep 24Jun 25Mar 26
12%9.2%6.8%4.3%1.9%%10.9%Jun 23Sep 24Mar 26
Revenue growth
Flat
latest +11.2% · span −19.6% to +11.2%
EPS growth
Flat
latest +114.6% · span −208.0% to +4,239.6%
ROCE
Rising
latest 10.9% · span 2.6%–10.9%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+11.2%−1.1%+6.0%+13.9%
Profit+170.7%−20.5%−8.7%+8.8%
EPS+114.5%−18.6%−7.4%+5.8%
Share price−9.1%+0.3%−4.9%+4.2%
Revenue YoY (Mar 26)
+17.7%
latest quarter vs a year ago
Profit YoY (Mar 26)
+19.9%
latest quarter vs a year ago
Revenue 10y
13.9%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

54.2/100 — rank 7 of 24 in Pesticides/Agrochemicals · 90% evidence confidence

UPL Ltd scores 54.2 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 20.6 + 9.3 + 12.5 + 11.8 = 54.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

UPL Ltd reported ₹18,335 Cr of revenue in the Mar 26 quarter, +17.7% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.9% a year. The last full year, FY26, came in at ₹51,839 Cr. The last four reported quarters add to ₹51,839 Cr.

FY26 revenue came in at ₹51,839 Cr (+11.2% on the year), capping 10 years at 13.9% compound. The latest quarter (Mar 26) printed ₹18,335 Cr, +17.7% year on year — the 8th consecutive quarter of year-over-year growth.

FY26 revenue ₹51,839 Cr (+11.2% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
13.9% a year over 10 years
RevenueYoY growth
57.9k70%43.4k46%28.9k22%14.5k−2.1%0−26%₹ Cr%₹51,83911.2%FY16FY21FY26
57.9k70%43.4k46%28.9k22%14.5k−2.1%0−26%₹ Cr%₹51,83911.2%FY16FY21FY26
Mar 26: ₹18,335 Cr (+17.7% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
8th straight quarter of growth
Revenue (quarterly)YoY growth
19.8k21%14.9k8.2%9.9k−5.0%5.0k−18%0−31%₹ Cr%₹18,33517.7%Jun 23Sep 24Mar 26
19.8k21%14.9k8.2%9.9k−5.0%5.0k−18%0−31%₹ Cr%₹18,33517.7%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +10.1% growth against the decade's 13.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.2% over the last 4 quarters against +9.7%/yr over the last 8 — stabilising.

06 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

UPL Ltd's operating margin is 19.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 22.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 19.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–22.0%.

🚨 Why the margin moved: operating margin went −1.3 pp year on year while gross margin went −0.3 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26: 18.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 13-year window.
within a 10.0–22.0% band over 13 years
operating marginYoY change (pp)
23%6.1%19%2.1%16%−2.0%13%−6.1%9.0%−10%%%18%3%FY14FY20FY26
23%6.1%19%2.1%16%−2.0%13%−6.1%9.0%−10%%%18%3%FY14FY20FY26
Mar 26: 19.0% operating margin (−1.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
22%17%16%7.0%10%−3.0%4.8%−13%−0.8%−23%%%19%−1%Jun 23Sep 24Mar 26
22%17%16%7.0%10%−3.0%4.8%−13%−0.8%−23%%%19%−1%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

UPL Ltd earned ₹1,294 Cr of net profit in the Mar 26 quarter, +19.9% year on year. Full-year FY26 profit was ₹2,220 Cr. The 10-year compound rate is 8.8%. That is 7.1% of the quarter's revenue. The same quarter a year earlier earned ₹1,079 Cr. 6 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹1,294 Cr, +19.9% year on year. On the full year, FY26 printed ₹2,220 Cr (+170.7%), and the 10-year compound rate is 8.8%.

FY26 profit ₹2,220 Cr (+170.7% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
8.8% a year over 10 years
Net profitYoY growth
4.9k196%3.1k105%1.3k14%−552−77%−2.4k−168%₹ Cr%₹2,220170.7%FY16FY21FY26
4.9k196%3.1k105%1.3k14%−552−77%−2.4k−168%₹ Cr%₹2,220170.7%FY16FY21FY26
Mar 26: ₹1,294 Cr (+19.9% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
1.5k71%685−114%−157−298%−998−483%−1.8k−668%₹ Cr%₹1,29419.9%Jun 23Sep 24Mar 26
1.5k71%685−114%−157−298%−998−483%−1.8k−668%₹ Cr%₹1,29419.9%Jun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 346% of UPL Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹7,855 Cr of operating cash against ₹2,220 Cr of profit. After ₹6,914 Cr of capital spending, ₹941 Cr was left as free cash.

FY26: operating cash of ₹7,855 Cr against reported profit of ₹2,220 Cr, leaving free cash of ₹941 Cr after ₹6,914 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 346% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹7,855 Cr vs profit ₹2,220 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 11-year window, annual resolution. FY19 reflects an acquisition year — point shown clipped.
346% of 3-year profit arrived as cash
Operating cashNet profitFree cash
11.1k7.6k4.1k648−2.8k₹ Cr₹7,855₹2,220₹941FY16FY21FY26
11.1k7.6k4.1k648−2.8k₹ Cr₹7,855₹2,220₹941FY16FY21FY26
FY26: CFO = 354% of profit (three-year rate 346%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
316%258%200%142%84%%300%FY16FY21FY26
316%258%200%142%84%%300%FY16FY21FY26

Why conversion sits at 346%: the cash cycle stretched 84 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

UPL Ltd's cash conversion cycle runs 135 days in FY26, up from 51 days in FY21. Capital spending ran ₹12,526 Cr over the last 3 years. At FY26 sales of ₹51,839 Cr each day of that cycle holds about ₹142 Cr, so roughly ₹19,173 Cr sits inside the business at any moment.

FY26: debtors at 126 days, inventory at 179 days — roughly 5.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 135 days, looser than FY21's 51.

The full loop: cash goes out to suppliers and production on day 0; stock waits 179 days to sell; customers pay about 126 days after that; and suppliers themselves are paid at 169 days — netting out to the 135-day cycle.

In money terms: at FY26 sales of ₹51,839 Cr, each day of the cycle holds about ₹142 Cr — so the 135-day loop keeps roughly ₹19,173 Cr sitting inside the business at any moment.

FY26: a 135-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 13-year window.
+84 days vs FY21
Cash cycleInventory daysDebtor daysPayable days
35227119111029days135d179d126d169dFY14FY17FY20FY23FY26
35227119111029days135d179d126d169dFY14FY20FY26

On the investment side: capital spending of ₹12,526 Cr over the last 3 fiscal years against ₹8,757 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹3,147 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹6,914 Cr, work-in-progress ₹3,147 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
steady investment
CapexWork-in-progress
31.5k23.6k15.7k7.9k0₹ Cr₹6,914₹3,147FY16FY18FY21FY23FY26
31.5k23.6k15.7k7.9k0₹ Cr₹6,914₹3,147FY16FY21FY26

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

10 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

UPL Ltd earns a ROCE of 10% in FY26. That is up from a trough of 3% in FY24. Return on invested capital clears the cost of that capital by −4.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.3% net margin on 0.56× asset turns.

FY26 ROCE is 10%, recovered from a FY24 trough of 3% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 4.3% net margin × 0.56× asset turns × 2.68× balance-sheet leverage ≈ 6.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 7.9% − 12.0% = a −4.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY26: ROCE 10% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 13-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY24's 3%
ROCEROIC (annual)WACC
24%18%13%7.0%1.5%%10%8%FY14FY20FY26
24%18%13%7.0%1.5%%10%8%FY14FY20FY26
Q4 FY26: ROCE 10.5% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
15%10%5.3%0.5%−4.3%%10.5%8.4%Q1 FY24Q2 FY25Q4 FY26
15%10%5.3%0.5%−4.3%%10.5%8.4%Q1 FY24Q2 FY25Q4 FY26
11 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

UPL Ltd carries total debt of ₹23,576 Cr against shareholder equity of ₹41,269 Cr as of Mar 26, a debt-to-equity of 0.57. On the annual view that ratio went from 0.91 in FY22 to 0.57 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹23,576 Cr against shareholder equity of ₹41,269 Cr — a debt-to-equity of 0.57. On the annual view, debt-to-equity went from 0.91 (FY22) to 0.57 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹23,576 Cr at 0.57× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
32.1k0.9×24.1k0.8×16.1k0.7×8.0k0.6×00.5×₹ Cr×₹23,5760.57×FY22FY24FY26
32.1k0.9×24.1k0.8×16.1k0.7×8.0k0.6×00.5×₹ Cr×₹23,5760.57×FY22FY24FY26
Mar 26: debt ₹23,576 Cr, debt-to-equity 0.57 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 12 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
37.7k1.1×28.3k0.9×18.9k0.8×9.4k0.7×00.5×₹ Cr×₹23,5760.57×Jun 23Sep 24Mar 26
37.7k1.1×28.3k0.9×18.9k0.8×9.4k0.7×00.5×₹ Cr×₹23,5760.57×Jun 23Sep 24Mar 26
12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 8.2 points of UPL Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 42.4% of the company. Domestic institutions moved −3.3 points over the same window, to 14.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +8.2 points over 8 quarters to 42.4%; Domestic institutions: −3.3 points over 8 quarters to 14.3%; Promoters: +1.0 points over 8 quarters to 33.5%.

Why the register moved: rotation — foreign institutions +8.2 points against domestic institutions −3.3 points over 8 quarters, with promoters +1.0 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Fiscal-year ends: promoters +1.0 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
44%35%26%17%7.5%%33.5%41.8%14.6%10.1%Mar 24Mar 25Mar 26
44%35%26%17%7.5%%33.5%41.8%14.6%10.1%Mar 24Mar 25Mar 26
Foreign institutions added 8.2 points over 8 quarters Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
45%36%26%17%7.2%%33.5%42.4%14.3%9.8%Sep 23Mar 25Jun 26
45%36%26%17%7.2%%33.5%42.4%14.3%9.8%Sep 23Mar 25Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

UPL Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

14 · Related companies · Pesticides/Agrochemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Titan Biotech Ltd524717 69.3/100Favorable setup78% evidence ASLEEP 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence 6.0/20 P/E 57.8× · PEG — 50% evidence 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence
Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Sharda Cropchem LtdSHARDACROP 65.3/100Favorable setup97% evidence ASLEEP 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence 18.5/25 ROCE 30.2% · OPM 17% 95% evidence 19.2/20 P/E 11.8× · PEG 0.26 100% evidence 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3Punjab Chemicals & Crop Protection LtdPUNJABCHEM 61.8/100Mixed-positive evidence81% evidence ASLEEP 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence 18.3/25 ROCE 18.6% · OPM 12% 95% evidence 12.1/20 P/E 21× · PEG — 50% evidence 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence
Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Bayer CropScience LtdBAYERCROP 61.7/100Mixed-positive evidence70% evidence ASLEEP 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence 8.5/20 P/E 387× · PEG — 15% evidence 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence
Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Dharmaj Crop Guard LtdDHARMAJ 61.1/100Mixed-positive evidence62% evidence TURNING 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence 10.6/20 P/E 16.6× · PEG — 15% evidence 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence
Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Advance Agrolife LtdADVANCE 56.3/100Thin evidence · provisional56% evidence TURNING 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence 10.1/20 P/E 22.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence
Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7UPL Ltdthis pageUPL 54.2/100Mixed-positive evidence90% evidence ASLEEP 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence 9.3/25 ROCE 10.1% · OPM 19% 100% evidence 12.5/20 P/E 28.3× · PEG 0.5 100% evidence 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence
Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8India Pesticides LtdIPL 54.0/100Mixed-positive evidence81% evidence TURNING 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence 13.6/25 ROCE 16.7% · OPM 14% 95% evidence 14.1/20 P/E 16.5× · PEG — 50% evidence 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence
Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Jubilant Ingrevia LtdJUBLINGREA 52.7/100Mixed-positive evidence93% evidence FADING 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence 10.2/25 ROCE 11.4% · OPM 15% 100% evidence 6.4/20 P/E 36.8× · PEG 2.37 65% evidence 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Bharat Rasayan LtdBHARATRAS 51.6/100Mixed-positive evidence77% evidence ASLEEP 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence 16.5/25 ROCE 17.4% · OPM 16% 95% evidence 14.7/20 P/E 13.3× · PEG — 50% evidence 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence
Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Bhagiradha Chemicals & Industries LtdBHAGCHEM 51.0/100Mixed-positive evidence88% evidence TURNING 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence 2.0/20 P/E 207× · PEG 3.04 100% evidence 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12GSP Crop Science LtdGSPCROP 50.4/100Thin evidence · provisional59% evidence TURNING 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence 14.3/25 ROCE 19% · OPM 9% 100% evidence 9.6/20 P/E 26.8× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence
Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Dhanuka Agritech LtdDHANUKA 46.6/100Mixed-negative evidence96% evidence ASLEEP 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence 13.0/20 P/E 15.6× · PEG 1.72 100% evidence 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence
Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Sumitomo Chemical India LtdSUMICHEM 45.4/100Mixed-negative evidence94% evidence TURNING 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence 19.0/25 ROCE 22.1% · OPM 22% 100% evidence 4.0/20 P/E 44.6× · PEG 4 100% evidence 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence
Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
15Rallis India LtdRALLIS 45.3/100Mixed-negative evidence91% evidence ASLEEP 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence 11.4/20 P/E 26.7× · PEG 0.89 100% evidence 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence
Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16NACL Industries LtdNACLIND 44.9/100Mixed-negative evidence94% evidence TURNING 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence 4.4/25 ROCE 8.1% · OPM 11% 100% evidence 3.8/20 P/E 171× · PEG 2.02 100% evidence 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence
Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Astec Lifesciences LtdASTEC 44.9/100Mixed-negative evidence63% evidence ASLEEP 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence
Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Meghmani Organics LtdMOL 44.3/100Mixed-negative evidence74% evidence TURNING 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence 9.4/25 ROCE 6.7% · OPM 18% 95% evidence 10.2/20 P/E 21.3× · PEG — 15% evidence 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence
Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Insecticides India LtdINSECTICID 43.8/100Mixed-negative evidence77% evidence ASLEEP 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence 13.0/25 ROCE 15.8% · OPM 6% 95% evidence 11.7/20 P/E 13.5× · PEG — 50% evidence 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence
Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Excel Industries LtdEXCELINDUS 43.1/100Mixed-negative evidence70% evidence TURNING 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence 8.6/25 ROCE 6.1% · OPM 8% 95% evidence 10.9/20 P/E 16.4× · PEG — 15% evidence 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence
Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Epigral LtdEPIGRAL 41.3/100Mixed-negative evidence94% evidence ASLEEP 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence 14.3/25 ROCE 15.5% · OPM 25% 100% evidence 16.5/20 P/E 17.3× · PEG 0.43 100% evidence 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence
Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
22P I Industries LtdPIIND 40.9/100Mixed-negative evidence90% evidence ASLEEP 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence 15.5/25 ROCE 15% · OPM 22% 100% evidence 10.6/20 P/E 34.7× · PEG 1.71 100% evidence 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence
Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Best Agrolife LtdBESTAGRO 29.7/100Adverse evidence81% evidence TURNING 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence 9.0/25 ROCE 5.2% · OPM 20% 95% evidence 7.0/20 P/E 22.9× · PEG — 50% evidence 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence
Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Heranba Industries LtdHERANBA 25.7/100Adverse evidence65% evidence ASLEEP 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence 1.2/25 ROCE -1.6% · OPM -7% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence
Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is UPL Ltd's share price today?

UPL Ltd trades at ₹604, −9.1% over the past year. The company is valued at ₹50,997 Cr. The stock sits at 16% of its 52-week range of ₹565–₹805, −6.9% versus its 200-day average. On the tape, the price is in a downtrend, 20 weeks in. — as of 31 July 2026.

What were UPL Ltd's latest quarterly results?

UPL Ltd reported revenue of ₹18,335 Cr and net profit of ₹1,294 Cr for the Mar 26 quarter. Revenue rose 17.7% and profit rose 19.9% year on year. Earnings per share were ₹12.57. The operating margin was 19.0%, 1.0 pp lower than a year earlier. — as of 31 July 2026.

What is UPL Ltd's revenue?

UPL Ltd reported revenue of ₹18,335 Cr in the Mar 26 quarter, +17.7% year on year. For the full FY26 fiscal year, revenue was ₹51,839 Cr (+11.2%). Over the last 10 years revenue compounded at 13.9% a year. — as of 31 July 2026.

What is UPL Ltd's profit?

UPL Ltd earned ₹1,294 Cr of net profit in the Mar 26 quarter, +19.9% year on year. Full-year FY26 profit was ₹2,220 Cr. The operating margin ran 19.0% in the latest quarter. — as of 31 July 2026.

What is UPL Ltd's market cap?

UPL Ltd's market capitalisation is ₹50,997 Cr at a share price of ₹604. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.

What is UPL Ltd's P/E ratio?

UPL Ltd trades at a P/E of 28.3×, at the 75th percentile of its own 10-year range, against a long-run median of 21.1×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.

Does UPL Ltd pay a dividend?

Yes — UPL Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in 12 of its last 13 reported fiscal years. One of those years shows a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.

Is UPL Ltd overvalued?

On its own history, UPL Ltd looks expensive against its own history: its P/E of 28.3× sits at the 75th percentile of its 10-year range (long-run median 21.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.

Is UPL Ltd growing?

Yes — UPL Ltd is growing: latest-quarter revenue +17.7% year on year, profit +19.9%, and the margin −1.0 pp at 19.0%. The 10-year compound rates are 13.9% (revenue) and 8.8% (profit). The earnings engine currently reads: improving — as of 31 July 2026.

How is UPL Ltd performing?

UPL Ltd is in a downtrend, 20 weeks in. Its latest quarter's revenue rose 17.7% and profit rose 19.9% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 26 weeks. This describes what the data did, not a rating. — as of 31 July 2026.

What stage is UPL Ltd in?

Mixed — no clean majority across the growth curves, ROCE lifting at 10.9% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +11.2% latest, eps growth +114.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.

Is UPL Ltd in an uptrend?

No — the price is in a downtrend (week 20 of stage 4), trading −6.9% versus its 200-day average and at 16% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.

Is UPL Ltd beating the market?

Not lately — on a trailing-13-week view UPL Ltd is currently behind the NIFTY 500 (26 weeks and counting; last ahead the week of 2026-02-20), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +115% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.

Will UPL Ltd's share price go up?

This page publishes no price forecast for UPL Ltd. What it measures instead: the share price is ₹604, the price is in a downtrend 20 weeks in. Its P/E of 28.3× sits at the 75th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.

Who owns UPL Ltd?

Promoters hold 33.5% of UPL Ltd, foreign institutions 42.4%, domestic institutions 14.3% and the public 9.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 8.2 points over 8 quarters. — as of 31 July 2026.

Does UPL Ltd have too much debt?

It is moderate — UPL Ltd's debt-to-equity is 0.68, and operating profit covers the interest bill 3×. FY26 borrowings were ₹23,576 Cr against equity of ₹34,696 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.

What is UPL Ltd's capex?

UPL Ltd spent ₹12,526 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹6,914 Cr, with ₹3,147 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.

What is UPL Ltd's cash flow?

UPL Ltd generated ₹7,855 Cr of operating cash flow in FY26 and ₹941 Cr of free cash flow after ₹6,914 Cr of capital spending. Reported profit that year was ₹2,220 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.

Is UPL Ltd's profit real cash?

Yes — over the last 3 fiscal years, 346% of UPL Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹7,855 Cr against reported profit of ₹2,220 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.

Where is UPL Ltd in its business cycle?

UPL Ltd's FY26 operating margin was 18.0%, against a 13-year band of 10.0%–22.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.

What could break the UPL Ltd story?

The sharpest disagreement: annual EPS moved +114.5% against a −9.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.

Is UPL Ltd a stock worth studying right now?

This is not investment advice. The machine read: UPL Ltd's earnings have outrun its stock. EPS grew +114.5% in a year against a −9.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI